Ian M. Bell, Chris Abell and Finian J. Leeper
Transition-state analogues based upon the 6-(hydroxymethyl)-13-azagona-1,3,5(10),8-tetraene structure (e.g., 40) have been designed and synthesized as part of a programme to elicit antibodies capable of catalysing cationic cyclisations. Methodology for conjugating such analogues to proteins has also been developed.